Literature DB >> 6043738

Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma.

S E Salmon, R K Shadduck, A Schilling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1967        PMID： 6043738

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  9 in total

1.  Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients.

Authors:  Hakan Kaya; Benjamin Peressini; Irfan Jawed; Danko Martincic; Ameer L Elaimy; Wayne T Lamoreaux; Robert K Fairbanks; Kevin A Weeks; Christopher M Lee
Journal:  Int J Hematol       Date:  2011-12-09       Impact factor: 2.490

Review 2.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

3.  Controversies in the treatment of plasma cell myeloma.

Authors:  D E Bergsagel
Journal:  Postgrad Med J       Date:  1985-02       Impact factor: 2.401

4.  Multiple myeloma. Clinical correlation of immunoglobulin changes with therapy. A report of 23 cases.

Authors:  C M Basch; E H Rosenbaum
Journal:  Calif Med       Date:  1969-01

Review 5.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Blood       Date:  2008-03-15       Impact factor: 22.113

6.  Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.

Authors:  Peter M Voorhees; Qing Chen; George W Small; Deborah J Kuhn; Sally A Hunsucker; Jeffrey A Nemeth; Robert Z Orlowski
Journal:  Br J Haematol       Date:  2008-03-06       Impact factor: 6.998

7.  Bence Jones proteins and light chains of immunoglobulins. XV. Effect of corticosteroids on synthesis and excretion of Bence Jones protein.

Authors:  A Solomon
Journal:  J Clin Invest       Date:  1978-01       Impact factor: 14.808

8.  Efficacy of prednisone in refractory multiple myeloma and measurement of glucocorticoid receptors. A Southwest Oncology Group study.

Authors:  V Gupta; E B Thompson; D Stock-Novack; S E Salmon; H I Pierce; J D Bonnet; D Chilton; J Beckford
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

Review 9.  Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion.

Authors:  Kenshi Suzuki
Journal:  Clin Exp Nephrol       Date:  2012-09-13       Impact factor: 2.801
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.